Cargando…

Utility of Circulating Cell-Free RNA Analysis for the Characterization of Global Transcriptome Profiles of Multiple Myeloma Patients

In this study, we evaluated the utility of extracellular RNA (exRNA) derived from the plasma of multiple myeloma (MM) patients for whole transcriptome characterization. exRNA from 10 healthy controls (HC), five newly diagnosed (NDMM), and 12 relapsed and refractory (RRMM) MM patients were analyzed a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Maoshan, Mithraprabhu, Sridurga, Ramachandran, Malarmathy, Choi, Kawa, Khong, Tiffany, Spencer, Andrew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6628062/ https://www.ncbi.nlm.nih.gov/pubmed/31242667 http://dx.doi.org/10.3390/cancers11060887

Ejemplares similares

DNA-Repair Gene Mutations Are Highly Prevalent in Circulating Tumour DNA from Multiple Myeloma Patients
por: Mithraprabhu, Sridurga, et al.
Publicado: (2019)

Circulating Tumour DNA Analysis for Tumour Genome Characterisation and Monitoring Disease Burden in Extramedullary Multiple Myeloma
por: Mithraprabhu, Sridurga, et al.
Publicado: (2018)

Circulating tumour DNA analysis in multiple myeloma
por: Mithraprabhu, Sridurga, et al.
Publicado: (2017)

Translational Potential of RNA Derived From Extracellular Vesicles in Multiple Myeloma
por: Reale, Antonia, et al.
Publicado: (2021)

Phase II trial of single‐agent panobinostat consolidation improves responses after sub‐optimal transplant outcomes in multiple myeloma
por: Mithraprabhu, Sridurga, et al.
Publicado: (2020)

Deactylase inhibition in myeloproliferative neoplasms
por: Mithraprabhu, Sridurga, et al.
Publicado: (2010)

Circulating tumour DNA analysis predicts relapse and improves risk stratification in primary refractory multiple myeloma
por: Mithraprabhu, Sridurga, et al.
Publicado: (2023)

Liquid biopsies for liquid tumors: emerging potential of circulating free nucleic acid evaluation for the management of hematologic malignancies
por: Hocking, Jay, et al.
Publicado: (2016)

Overcoming inherent resistance to histone deacetylase inhibitors in multiple myeloma cells by targeting pathways integral to the actin cytoskeleton
por: Mithraprabhu, S, et al.
Publicado: (2014)

Combination of Histone Deacetylase Inhibitor Panobinostat (LBH589) with β-Catenin Inhibitor Tegavivint (BC2059) Exerts Significant Anti-Myeloma Activity Both In Vitro and In Vivo
por: Savvidou, Ioanna, et al.
Publicado: (2022)

Changes in immune cell populations following KappaMab, lenalidomide and low‐dose dexamethasone treatment in multiple myeloma
por: Norton, Samuel E, et al.
Publicado: (2023)

Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14)
por: Kalff, Anna, et al.
Publicado: (2021)

Cell-free DNA chromosome copy number variations predict outcomes in plasma cell myeloma
por: Qiang, Wanting, et al.
Publicado: (2023)

Editorial: Understanding the RNA Species in the Extracellular Vesicles of Multiple Myeloma
por: Chen, Maoshan, et al.
Publicado: (2022)

Heavy menstrual bleeding and dysmenorrhea are improved by Magnetic Resonance Guided Focused Ultrasound Surgery (MRgFUS) of adenomyosis
por: Jayaram, Ramya, et al.
Publicado: (2016)

Global Regulator MorA Affects Virulence-Associated Protease Secretion in Pseudomonas aeruginosa PAO1
por: Ravichandran, Ayshwarya, et al.
Publicado: (2015)

The Role of Chaperone-Mediated Autophagy in Bortezomib Resistant Multiple Myeloma
por: Nikesitch, Nicholas, et al.
Publicado: (2021)

Sperm chromatin structure assay versus sperm chromatin dispersion kits: Technical repeatability and choice of assisted reproductive technology procedure
por: B, Vidya Laxme, et al.
Publicado: (2020)

Genome-wide profiling of 5-hydroxymethylcytosines in circulating cell-free DNA reveals population-specific pathways in the development of multiple myeloma
por: Chiu, Brian C.-H., et al.
Publicado: (2022)

Mining the Plasma Cell Transcriptome for Novel Cell Surface Proteins
por: Trezise, Stephanie, et al.
Publicado: (2018)

Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma
por: Manier, S., et al.
Publicado: (2018)

The level and integrity of plasma circulating cell-free DNA in patients with primary multiple myeloma
por: Shen, Qian, et al.
Publicado: (2022)

Monitoring multiple myeloma by next-generation sequencing of V(D)J rearrangements from circulating myeloma cells and cell-free myeloma DNA
por: Oberle, Anna, et al.
Publicado: (2017)

The Utility of Euroflow MRD Assessment in Real-World Multiple Myeloma Practice
por: Turner, Rose, et al.
Publicado: (2022)

Clinical Significance of Circulating Cell-Free DNA Detection in Multiple Myeloma: A Meta-Analysis
por: Ye, Xueshi, et al.
Publicado: (2022)

Monitoring multiple myeloma in the peripheral blood based on cell-free DNA and circulating plasma cells
por: Mack, Elisabeth K. M., et al.
Publicado: (2022)

Circulating microRNAs and Their Role in Multiple Myeloma
por: Federico, Cinzia, et al.
Publicado: (2019)

Deep Transcriptome Profiling of Multiple Myeloma Using Quantitative Phenotypes
por: Griffin, Rosalie, et al.
Publicado: (2023)

Label-Free Enrichment of Circulating Tumor Plasma Cells: Future Potential Applications of Dielectrophoresis in Multiple Myeloma
por: Musso, Nicolò, et al.
Publicado: (2022)

Innovative Agents in Multiple Myeloma
por: Faiman, Beth, et al.
Publicado: (2014)

Liquid biopsy by analysis of circulating myeloma cells and cell-free nucleic acids: a novel noninvasive approach of disease evaluation in multiple myeloma
por: Li, Shuchan, et al.
Publicado: (2023)

Detection and Characterization of Circulating Tumour Cells in Multiple Myeloma
por: Zhang, Liangxuan, et al.
Publicado: (2016)

The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma
por: Mishima, Yuji, et al.
Publicado: (2017)

Circulating biosignatures in multiple myeloma and their role in multidrug resistance
por: Krishnan, S. Rajeev, et al.
Publicado: (2023)

Immune microenvironment characteristics in multiple myeloma progression from transcriptome profiling
por: Wang, Jin, et al.
Publicado: (2022)

Utility of Serum Free Light Chain Measurements in Multiple Myeloma Patients Not Achieving Complete Response to Therapy
por: Moustafa, Muhamad Alhaj, et al.
Publicado: (2015)

Utilizing BMP-2 muteins for treatment of multiple myeloma
por: Seher, Axel, et al.
Publicado: (2017)

Functional Impact of Genomic Complexity on the Transcriptome of Multiple Myeloma
por: Ziccheddu, Bachisio, et al.
Publicado: (2021)

Multiple Myeloma: Risk Stratification and Toxicity Management
por: Richards, Tiffany, et al.
Publicado: (2018)

Global Epigenetic Regulation of MicroRNAs in Multiple Myeloma
por: Zhang, Wenjing, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_1uknbgph3q08ilqg9o4tia833g